ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 113

Power Doppler Signal Is Frequently Positive Among Patients with Rheumatoid Arthritis in Clinical Remission and Normal Serum Matrix Metalloproteinase-3 (MMP-3) Levels

Tadashi Okano1, Tatsuya Koike2, Masahiro Tada1, Kenji Mamoto1, Yuko Sugioka1, Atsuko Kamiyama2 and Hiroaki Nakamura1, 1Orthopedic Surgery, Osaka City University Medical School, Osaka, Japan, 2Rheumatosurgery, Osaka City University Medical School, Osaka, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Doppler ultrasound, matrix metalloproteinase (MMP), remission and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging of Rheumatic Diseases: Ultrasound, Nuclear Medicine and Fluorescence Imaging

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Serum matrix metalloproteinase-3 (MMP-3) is useful bio markers of synovitis associated with rheumatoid arthritis (RA). Ultrasonography (US) has recently become more popular as a method of evaluating joint synovitis. The purpose of this study is to determine the significance of grey scale ultrasonography (GSUS) and power Doppler ultrasonography (PDUS) scores by comparison with serum biomarkers and clinical disease activity assessment.

Methods:  

We selected 151 consecutive patients with RA at our hospital outpatient clinic. The patients underwent musculoskeletal ultrasonography at 26 synovial sites in the following joints: bilateral first to fifth MCP (dorsal recess), first IP and second to fifth PIP (dorsal recess) joints and the wrists (dorsal radial, dorsal median and dorsal ulnar). The GS and power PD signals were scored in each joint using a scale from 0 to 3. The GSUS and PDUS scores are the sums of the scores obtained for the 26 synovial sites. Correlations among serum CRP, ESR and MMP-3 values and disease activity evaluated using the DAS28-ESR, DAS28-CRP, SDAI, CDAI were analyzed along with the PDUS positive ratio in patients in remission and in patients with normal MMP-3 values.

Results:

The clinical characteristics of the 151 patients (128 females and 23 males; mean age, 60.5 ± 13.1 years) with RA were as follows. They received only DMARDs (n = 80), and biological DMARDs (n = 71). The GSUS and PDUS scores were significantly and positively correlated with ESR, CRP, MMP-3, DAS28-ESR, DAS28-CRP, SDAI and CDAI. The PDUS score >1 was positive in 28 of 34 patients (82.3%) in remission with DAS28-CRP (< 2.6) and in 52 of 61 (85.2%) with normal serum MMP-3 levels. The PDUS score >2 was positive in 10 of 34 (29.4%) patients in remission with DAS28-CRP and in 30 of 61 (49.2%) with normal serum MMP-3 levels. The levels of PDUS score in the remission patients using biological DMARDs was less than the remission patients using only DMARDs.

Conclusion:  

Both GSUS and PDUS scores were closely correlated with clinical disease activity and serum biomarkers. These results indicate that US findings accurately reflect the pathogenesis of RA. However, patients in remission and normal serum MMP-3 levels also had a high rate of positive PD scores. We considered that US is more accurate for clinically evaluating patients with RA.


Disclosure:

T. Okano,
None;

T. Koike,

Chugai Pharmaceutical,

2,

Eli Lilly Japan,

8,

Novartis Pharmaceutical Corporation,

2,

Teijin Pharma,

8,

Bristol-Myers Squibb,

5,

Ono Pharmaceutical,

8,

Santen Pharmaceutical,

8,

Eisai,

8,

Abbott Japan,

8,

Mitsubishi Tanabe Pharma Corporation,

2,

Takeda Pharmaceutical,

8,

Astellas Pharma Inc.,

8,

Pfizer Japan Inc.,

8,

Janssen Pharmaceutical,

2,

Asahi Kasei Pharma Corporation,

8,

Daiichi Sankyo Company,

2;

M. Tada,
None;

K. Mamoto,
None;

Y. Sugioka,
None;

A. Kamiyama,
None;

H. Nakamura,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/power-doppler-signal-is-frequently-positive-among-patients-with-rheumatoid-arthritis-in-clinical-remission-and-normal-serum-matrix-metalloproteinase-3-mmp-3-levels/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology